<DOC>
	<DOCNO>NCT01905592</DOCNO>
	<brief_summary>The purpose study compare progression-free survival ( PFS ) patient advanced/metastatic breast cancer BRCA gene change treat niraparib compare treated physician 's choice</brief_summary>
	<brief_title>A Phase III Trial Niraparib Versus Physician 's Choice HER2 Negative , Germline BRCA Mutation-positive Breast Cancer Patients</brief_title>
	<detailed_description>This phase III , randomize , open label , multicenter , control trial niraparib versus physician 's choice previously-treated , HER2 negative , germline BRCA mutation-positive breast cancer patient . Niraparib orally active parp inhibitor . Niraparib ( 2:1 ratio ) administer daily continuously 21-day cycle . Physician 's choice administer 21-day cycle . Health-related quality life measure . The Safety tolerability assess clinical review adverse event ( AEs ) , physical examination , electrocardiogram ( ECGs ) , safety laboratory value .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Niraparib</mesh_term>
	<criteria>1 . Germline BRCA1 BRCA2 mutation ; patient unknown BRCA status meet NCCN BRCA screen criterion screen BRCA mutation . 2 . Metastatic locally advance disease amenable resection radiation curative intent . 3 . Up 2 prior cytotoxic regimen advance metastatic breast cancer patient prior cytotoxic regimen advance metastatic disease allow relapse within 12 month ( neo ) adjuvant cytotoxic therapy include taxane and/or anthracycline , contraindicate . 4 . Prior therapy include taxane and/or anthracycline ( unless contraindication ) neoadjuvant , adjuvant , advanced/metastatic setting . . Hormone receptor positive patient must also hormone resistant disease ( progression least one prior hormonal therapy ) chemotherapy indicate . 5 . ECOG performance status 02 6 . Adequate bone marrow , kidney liver function 1 . Patients platinum resistant cancer 2 . Symptomatic uncontrolled brain metastasis 3 . Prior diagnosis Stage IV ovarian cancer ; Stage III ovarian cancer must 5year diseasefree interval ; Stage II ovarian cancer must 2year diseasefree interval 4 . Known hypersensitivity component niraparib 5 . Invasive cancer ovarian cancer within 2 year ( except basal squamous cell carcinoma skin definitely treat ) 6 . Pregnant breast feeding patient 7 . Immunocompromised patient 8 . Known active Hepatitis B C 9 . Prior treatment PARP inhibitor 10 . Known history myelodysplastic syndrome ( MDS ) . 11. known persistent ( &gt; 4 week ) &gt; /= grade 3 toxicity fatigue prior cancer treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Human Epidermal Growth Factor 2 Negative Carcinoma Breast</keyword>
	<keyword>BRCA1 Gene Mutation</keyword>
	<keyword>BRCA2 Gene Mutation</keyword>
	<keyword>Parp Inhibitor</keyword>
	<keyword>BRCA</keyword>
</DOC>